阅读说明：本技术 一种雨生红球藻胶囊的制备工艺 (Preparation process of haematococcus pluvialis capsules ) 是由 杨振坤 于 2021-03-24 设计创作，主要内容包括：本发明公布了一种雨生红球藻胶囊的制备工艺,原料组成成分按重量份数由以下比例组成：雨生红球藻120-130份、卵磷脂10-15份、番茄红素12-13份、预胶化淀粉120-130份、硬脂酸镁3-5份、二氧化硅2-3份、维生素C 3-5份、维生素D 2-4份、维生素E 2-3份、柠檬汁5-10份、核桃粉3-5份、鲑鱼蛋白粉10-15份、海藻粉6-14份。本发明工艺简单,采用大量天然材料进行制备,有效丰富其营养,提高抗氧化性,节约成本,提高综合经济效益。(The invention discloses a preparation process of haematococcus pluvialis capsules, which comprises the following raw materials in parts by weight: 130 parts of haematococcus pluvialis 120-containing materials, 10-15 parts of lecithin, 12-13 parts of lycopene, 130 parts of pregelatinized starch 120-containing materials, 3-5 parts of magnesium stearate, 2-3 parts of silicon dioxide, 3-5 parts of vitamin C, 2-4 parts of vitamin D, 2-3 parts of vitamin E, 5-10 parts of lemon juice, 3-5 parts of walnut powder, 10-15 parts of salmon protein powder and 6-14 parts of seaweed powder. The invention has simple process, adopts a large amount of natural materials for preparation, effectively enriches the nutrition, improves the oxidation resistance, saves the cost and improves the comprehensive economic benefit.)

1. A preparation process of haematococcus pluvialis capsules is characterized by comprising the following steps: the raw materials comprise the following components in parts by weight: 130 parts of haematococcus pluvialis 120-containing materials, 10-15 parts of lecithin, 12-13 parts of lycopene, 130 parts of pregelatinized starch 120-containing materials, 3-5 parts of magnesium stearate, 2-3 parts of silicon dioxide, 3-5 parts of vitamin C, 2-4 parts of vitamin D, 2-3 parts of vitamin E, 5-10 parts of lemon juice, 3-5 parts of walnut powder, 10-15 parts of salmon protein powder and 6-14 parts of seaweed powder;

the process comprises the following steps:

homogenizing Haematococcus pluvialis in a high-pressure homogenizer at 0-4 deg.C and 40-150MP in a clean area of 30 ten thousand, and sieving to obtain Haematococcus pluvialis powder;

adding appropriate amount of lemon juice, salmon protein and seaweed meal into a stirrer for stirring, slowly adding the Haematococcus pluvialis meal for multiple times at a stirring speed of 150-;

putting a proper amount of pregelatinized starch, magnesium stearate and silicon dioxide into a stirrer, mixing and stirring at room temperature, and sieving through a 60-100 mesh sieve to obtain a mixture B;

adding a proper amount of lecithin into the mixture B, stirring, sequentially adding lycopene and walnut powder at a stirring speed of 200-250r/min, stirring for 3-5min, adding the mixture A, mixing at 10-15 ℃, adding vitamin C, vitamin D and vitamin E in the mixing process to fully and uniformly stir, sieving, and then adding into a homogenizer for secondary homogenization to obtain total dry powder;

filling a proper amount of total dry powder into the capsule to ensure that the mass of the capsule is 0.25 g/grain, and polishing, selecting, internally packing and externally packing the capsule.

2. The process according to claim 1, wherein the capsule is prepared from Haematococcus pluvialis, and comprises the following steps: haematococcus pluvialis: pregelatinized starch: the ratio of the gravimetric components of lycopene =10:10: 1.

Technical Field

The invention relates to a preparation process of haematococcus pluvialis capsules.

Background

Haematococcus pluvialis (Haematococcus pluvialis) is a widely distributed unicellular green alga, can form chlamydospores under adverse conditions and can accumulate a large amount of a plurality of carotenoids with physiological functions, mainly comprises astaxanthin, astaxanthin monoester, astaxanthin diester, lutein, beta-carotene, echinenone, canthaxanthin and the like, and 80 percent of the astaxanthin and the esters thereof. Haematococcus pluvialis is the organism with the highest astaxanthin content in the natural world, and can reach 1.5-4% of dry weight.

Astaxanthin has the highest antioxidant activity due to the carbonyl group and hydroxyl group on the terminal ring, 10 times of that of beta-carotene, 60 times of that of procyanidin, and 550 times of that of vitamin E (Miki W., Biological functions and activities of animal carotenoids, pure appl. chem., 1991, Vol.63, No.1, pp.141-146). In addition, astaxanthin has a number of strong physiological effects (Pashkow FJ, Watumull DG, Campbell CL. Astaxanthin: alpha novel) such as inhibiting tumorigenesis, enhancing immune function, and protecting against UV damage

A porous treatment for oxidative stress and inflammation in a carbonaceous disease. am J. Cardiol.2008May22; 101 (10A): 58D-68D.), thereby being widely applied to the fields of food, medicine, cosmetics, health products, aquaculture and the like. FDA approval has been obtained in the united states to allow entry into the health care market as a new dietary ingredient. The astaxanthin has the advantages of super-strong oxidation resistance, various biological activities and bright red color, so that the astaxanthin has wide application prospect and market potential, and is widely applied to the fields of aquatic products, poultry breeding industry, food, health care products, cosmetics, pharmaceutical industry and the like.

A large amount of chemical substances are added in the existing preparation process of haematococcus pluvialis capsules, so that the preparation difficulty is increased while antioxidation is realized, meanwhile, certain residues are left on a body, the haematococcus pluvialis capsules are not easy to excrete out of the body, and meanwhile, the internal nutrition content is low, so that the haematococcus pluvialis capsules are not beneficial to long-term development.

Disclosure of Invention

The invention aims to provide a preparation process of haematococcus pluvialis capsules, so as to solve the problems in the background technology.

In order to achieve the purpose, the invention provides the following technical scheme: a preparation process of haematococcus pluvialis capsules comprises the following raw material components in parts by weight: 130 parts of haematococcus pluvialis 120-containing materials, 10-15 parts of lecithin, 12-13 parts of lycopene, 130 parts of pregelatinized starch 120-containing materials, 3-5 parts of magnesium stearate, 2-3 parts of silicon dioxide, 3-5 parts of vitamin C, 2-4 parts of vitamin D, 2-3 parts of vitamin E, 5-10 parts of lemon juice, 3-5 parts of walnut powder, 10-15 parts of salmon protein powder and 6-14 parts of seaweed powder;

the process comprises the following steps:

(1) homogenizing Haematococcus pluvialis in a high-pressure homogenizer at 0-4 deg.C and 40-150MP in a clean area of 30 ten thousand, and sieving to obtain Haematococcus pluvialis powder;

(2) adding appropriate amount of lemon juice, salmon protein and seaweed meal into a stirrer for stirring, slowly adding the Haematococcus pluvialis meal for multiple times at a stirring speed of 150-;

(3) putting a proper amount of pregelatinized starch, magnesium stearate and silicon dioxide into a stirrer, mixing and stirring at room temperature, and sieving through a 60-100 mesh sieve to obtain a mixture B;

(4) adding a proper amount of lecithin into the mixture B, stirring, sequentially adding lycopene and walnut powder at a stirring speed of 200-250r/min, stirring for 3-5min, adding the mixture A, mixing at 10-15 ℃, adding vitamin C, vitamin D and vitamin E in the mixing process to fully and uniformly stir, sieving, and then adding into a homogenizer for secondary homogenization to obtain total dry powder;

(5) filling a proper amount of total dry powder into the capsule to ensure that the mass of the capsule is 0.25 g/grain, and polishing, selecting, internally packing and externally packing the capsule.

Preferably, haematococcus pluvialis: pregelatinized starch: the ratio of the gravimetric components of lycopene =10:10: 1.

Compared with the prior art, the invention has the beneficial effects that:

the production process is simple and easy to operate, the lycopene and the vitamin E are added to effectively prevent oxidation, the lemon juice is used to enhance the oxidation resistance and the anticancer effect of haematococcus pluvialis, the homogenizing means is used to effectively remove internal free radicals, the integral stability is enhanced, the human body absorption force is enhanced, the fineness of the taste can be effectively improved, the working efficiency and the precision are improved, the cost is saved, the comprehensive economic benefit is improved, meanwhile, the pregelatinized starch is used to enhance the cohesiveness of the structure, the magnesium stearate is used to have a good lubricating effect, the lecithin, the salmon protein and the seaweed meal are used to effectively improve the protein content, the immunity and the absorption force are enhanced, and the trace elements are used to effectively enrich the nutrition.

Detailed Description

The technical solutions in the embodiments of the present invention are clearly and completely described below, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.

Example one

The invention provides a technical scheme that: a preparation process of haematococcus pluvialis capsules comprises the following raw material components in parts by weight: 122 parts of haematococcus pluvialis, 14 parts of lecithin, 12 parts of lycopene, 122 parts of pregelatinized starch, 4 parts of magnesium stearate, 3 parts of silicon dioxide, 4 parts of vitamin C, 4 parts of vitamin D, 2 parts of vitamin E, 8 parts of lemon juice, 4 parts of walnut powder, 14 parts of salmon protein powder and 12 parts of seaweed powder;

the process comprises the following steps:

(1) under the conditions that the temperature is 3 ℃, the pressure is 120MP and 30 ten thousand clean areas exist, putting haematococcus pluvialis into a high-pressure homogenizer for homogenization and sieving to obtain haematococcus pluvialis powder;

(2) adding appropriate amount of lemon juice, salmon protein and seaweed meal into a stirrer, stirring, slowly adding Haematococcus pluvialis meal for multiple times at a stirring speed of 160r/min for 13min, and sieving the stirred mixture with a 100-mesh sieve to obtain a mixture A;

(3) putting a proper amount of pregelatinized starch, magnesium stearate and silicon dioxide into a stirrer, mixing and stirring at room temperature, and sieving through a 100-mesh sieve to obtain a mixture B;

(4) adding a proper amount of lecithin into the mixture B, stirring, sequentially adding lycopene and walnut powder after stirring, wherein the stirring speed is 230r/min, stirring for 5min, adding the mixture A, mixing at the temperature of 12 ℃, adding vitamin C, vitamin D and vitamin E in the mixing process to fully and uniformly stir, sieving, and then adding into a homogenizer for secondary homogenization to obtain total dry powder;

(5) filling a proper amount of total dry powder into the capsule to ensure that the mass of the capsule is 0.25 g/grain, and polishing, selecting, internally packing and externally packing the capsule.

Example two

The invention provides a technical scheme that: a preparation process of haematococcus pluvialis capsules comprises the following raw material components in parts by weight: 120 parts of haematococcus pluvialis, 15 parts of lecithin, 12 parts of lycopene, 120 parts of pregelatinized starch, 5 parts of magnesium stearate, 2 parts of silicon dioxide, 3 parts of vitamin C, 4 parts of vitamin D, 2 parts of vitamin E, 10 parts of lemon juice, 3 parts of walnut powder, 15 parts of salmon protein powder and 6 parts of seaweed powder;

the process comprises the following steps:

(1) under the conditions that the temperature is 4 ℃, the pressure is 40MP and 30 ten thousand clean areas exist, putting haematococcus pluvialis into a high-pressure homogenizer for homogenization and sieving to obtain haematococcus pluvialis powder;

(2) adding appropriate amount of lemon juice, salmon protein and seaweed meal into a stirrer for stirring, slowly adding Haematococcus pluvialis meal for multiple times at a stirring speed of 180r/min for 10min, and sieving the stirred mixture through a 100-mesh sieve to obtain a mixture A;

(3) putting a proper amount of pregelatinized starch, magnesium stearate and silicon dioxide into a stirrer, mixing and stirring at room temperature, and sieving through a 60-mesh sieve to obtain a mixture B;

(4) adding a proper amount of lecithin into the mixture B, stirring, sequentially adding lycopene and walnut powder after stirring, wherein the stirring speed is 250r/min, adding the mixture A after stirring for 3min, mixing at the temperature of 15 ℃, adding vitamin C, vitamin D and vitamin E in the mixing process to fully and uniformly stir, sieving, and then adding into a homogenizer for secondary homogenization to obtain total dry powder;

(5) filling a proper amount of total dry powder into the capsule to ensure that the mass of the capsule is 0.25 g/grain, and polishing, selecting, internally packing and externally packing the capsule.

EXAMPLE III

The invention provides a technical scheme that: a preparation process of haematococcus pluvialis capsules comprises the following raw material components in parts by weight: 130 parts of haematococcus pluvialis, 10 parts of lecithin, 13 parts of lycopene, 130 parts of pregelatinized starch, 3 parts of magnesium stearate, 3 parts of silicon dioxide, 5 parts of vitamin C, 2 parts of vitamin D, 3 parts of vitamin E, 5 parts of lemon juice, 5 parts of walnut powder, 10 parts of salmon protein powder and 14 parts of seaweed powder;

the process comprises the following steps:

(1) under the environment of 0 ℃ and 150MP pressure and 30 ten thousand clean areas, putting haematococcus pluvialis into a high-pressure homogenizer for homogenization and sieving to obtain haematococcus pluvialis powder;

(2) adding appropriate amount of lemon juice, salmon protein and seaweed meal into a stirrer for stirring, slowly adding Haematococcus pluvialis meal for multiple times at a stirring speed of 150r/min for 15min, and sieving the stirred mixture through a 60-mesh sieve to obtain a mixture A;

(3) putting a proper amount of pregelatinized starch, magnesium stearate and silicon dioxide into a stirrer, mixing and stirring at room temperature, and sieving through a 100-mesh sieve to obtain a mixture B;

(4) adding a proper amount of lecithin into the mixture B, stirring, sequentially adding lycopene and walnut powder after stirring, wherein the stirring speed is 200r/min, adding the mixture A after stirring for 5min, mixing at the temperature of 10 ℃, adding vitamin C, vitamin D and vitamin E in the mixing process to fully and uniformly stir, sieving, and then adding into a homogenizer for secondary homogenization to obtain total dry powder;

(5) filling a proper amount of total dry powder into the capsule to ensure that the mass of the capsule is 0.25 g/grain, and polishing, selecting, internally packing and externally packing the capsule.

In the above examples, haematococcus pluvialis: pregelatinized starch: the ratio of the gravity components of the lycopene =10:10: 1; in conclusion, example 1 is the best practice to improve the oxidation resistance and anticancer effect, and is nutritious, easy to absorb, and improves the immunity.

Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.